Noga Shem-Tov
Overview
Explore the profile of Noga Shem-Tov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sdayoor I, Shouval R, Fried S, Marcus R, Danylesko I, Yerushalmi R, et al.
Blood Adv
. 2025 Jan;
PMID: 39774788
Pulmonary function tests (PFT) are recommended for hematopoietic cell transplantation (HCT) evaluation. However, their prognostic value in chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We assessed the predictive significance...
2.
Danylesko I, Shem-Tov N, Yerushalmi R, Jacoby E, Toren A, Shouval R, et al.
Curr Res Transl Med
. 2024 Sep;
72(4):103471.
PMID: 39305562
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the...
3.
Benjamini O, Fried S, Shouval R, Flynn J, Beyar-Katz O, Leslie L, et al.
Haematologica
. 2024 Jun;
109(11):3566-3577.
PMID: 38899351
The activity of anti-CD19 chimerci antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B-cell lymphoma (LBCL) is largely unknown. In a...
4.
Davidov Y, Shem-Tov N, Yerushalmi R, Hod T, Ben-Ari Z, Nagler A, et al.
Bone Marrow Transplant
. 2024 Apr;
59(8):1070-1075.
PMID: 38658660
Sinusoidal Obstructive Syndrome (SOS) is a life-threatening complication after hematopoietic stem-cell transplantation (HSCT), characterized by post-sinusoidal portal hypertension. FibroScan is used to assess portal hypertension non-invasively. We assessed transient elastography...
5.
Youngster I, Eshel A, Geva M, Danylesko I, Henig I, Zuckerman T, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):409-416.
PMID: 38212672
Acute graft-versus-host disease (aGvHD) is a serious complication of allogeneic hematopoietic stem-cell transplantation with limited treatment options. The gut microbiome plays a critical role in aGvHD pathogenesis. Fecal microbiota transplantation...
6.
Fried S, Shkury E, Itzhaki O, Sdayoor I, Yerushalmi R, Shem-Tov N, et al.
Leuk Lymphoma
. 2023 Aug;
64(12):1956-1963.
PMID: 37565578
Patients with relapsed/refractory follicular lymphoma (R/R-FL) often require multiple treatment lines. We performed a phase 1b/2 single-center clinical trial of autologous point-of-care anti-CD19 chimeric antigen receptor (CAR) T-cells in R/R-FL...
7.
Yerushalmi Y, Shem-Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, et al.
Haematologica
. 2022 Dec;
108(7):1782-1792.
PMID: 36475520
Second allogeneic hematopoietic stem-cell transplantation (HSCT2) is a therapeutic option for patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) relapsing after a first transplant (HSCT1). However, patients allocated to HSCT2...
8.
Fried S, Shouval R, Walji M, Flynn J, Yerushalmi R, Shem-Tov N, et al.
Transplant Cell Ther
. 2022 Nov;
29(2):99-107.
PMID: 36343892
Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has transformed the care of patients with relapsed/refractory large B cell lymphoma (LBCL). However, approximately 60% of CAR-T recipients ultimately will experience...
9.
Tomas A, Fein J, Fried S, Flynn J, Devlin S, Fingrut W, et al.
Leukemia
. 2022 Nov;
37(1):154-163.
PMID: 36335261
Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data guiding management are limited. We describe outcomes and features following CAR-T treatment failure. Of 305 adults who...
10.
Fried S, Shouval R, Varda-Bloom N, Besser M, Yerushalmi R, Shem-Tov N, et al.
Leuk Lymphoma
. 2022 Sep;
63(14):3385-3393.
PMID: 36111694
Tisagenlecleucel (tisa-cel) is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed/refractory large B-cell lymphoma. Outcomes of patients with out-of-commercial specification (OOS) CAR T products are...